Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna projects significant growth in product sales, with expectations of $1.73 billion in 2025 rising to $2.15 billion in 2026, underscoring increasing market demand for its mRNA products. The company's recent $1.5 billion debt deal enhances its balance sheet and provides flexibility to navigate uncertainties while pursuing future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to expand gross margins, which have rebounded from 30% in 2023 to 50% in 2025, projecting a positive financial trajectory as the company aims for cash break-even by 2028.

Bears say

Moderna's financial outlook is hindered by a significant decline in COVID vaccine sales, which dropped from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced guidance for 2025 stemming from anticipated lower vaccination rates as the pandemic transitions to endemic status. The firm's revised projections indicate a decrease in long-term COVID revenue expectations from $3.5 billion to $2.5 billion annually, compounded by poor negotiations in the European market, leading to low sales expectations for 2024 and potentially 2025. Furthermore, overall enterprise value has been adjusted from $22.12 billion to $21.53 billion, reflecting ongoing challenges and headwinds in both their RSV and COVID programs.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.